Jose Belderbos, MD, PhD, of the Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses the local failure (LF) and regional failure (RF) results from the Phase II PET-Boost trial (NCT01024829) in patients with non-small cell lung cancer (NSCLC). In this trial NSCLC patients were treated with hypofractioned dose escalation to either the primary tumor as a whole (arm A) or the high FDG-uptake region inside the primary tumor (arm B). In total, 107 patients were randomized in the trial and concurrent/sequential/no chemotherapy was allowed. Excellent local control rates were observed in both treatment arms. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.